A straightforward blood test measuring a specific tau protein, p-tau217, may forecast not only who is likely to develop Alzheimer’s but also roughly when symptoms will start. Scientists at Washington University School of Medicine analyzed longitudinal data to see if blood levels of p-tau217 act like a biological clock for disease onset. Their model combines age and protein concentration to estimate symptom timing within a few years’ margin of error.
Tau is a protein that normally helps stabilize the structure of nerve cells, but when it becomes abnormally phosphorylated it forms tangles that disrupt brain wiring. The p-tau217 variant is one form that shows up in the brain as these tangles and appears to track the disease process. Watching this protein rise could flag the earliest stage of Alzheimer’s long before memory trouble shows up.
Up to now, brain imaging and spinal fluid tests have been the ways to spot these changes, but those approaches are costly and technically demanding. The team wanted a simpler, cheaper method that could be scaled to large groups and routine clinical practice. A blood test that reliably mirrors what scans show would be a game changer for screening and research recruitment.
The study, published in Nature Medicine, looked at data from more than 600 older adults enrolled in two long-running Alzheimer’s projects, comparing blood samples with cognitive trajectories over time. By plotting p-tau217 against age and decline, researchers found a consistent pattern in how the marker rises before symptoms appear. “We show that a single blood test measuring p-tau217 can provide a rough estimate of when an individual is likely to develop symptoms of Alzheimer’s disease,” lead author Kellen K. Petersen, PhD, instructor of neurology at Washington University in St. Louis, told Fox News Digital.
The timing the team uncovered varied with age, suggesting the same biomarker shift can mean different speeds of progression depending on when it happens. Older adults whose p-tau217 became abnormal later in life tended to convert to symptomatic disease much faster than those with earlier abnormality. “For example, people who first had abnormal p-tau217 levels around age 60 didn’t develop Alzheimer’s symptoms for about 20 years, whereas those who first had abnormal p-tau217 levels around age 80 developed symptoms after only about 10 years,” Petersen said.
Those dynamics hint that brain reserve, comorbidities, or age-related vulnerability changes how quickly pathology translates into symptoms, and they offer a way to stratify people for trials. “This could transform how researchers design clinical trials and, eventually, how clinicians identify people at highest risk for cognitive decline associated with Alzheimer’s years before decline begins,” Chicago-based Rebecca M. Edelmayer, PhD, vice president of scientific engagement at the Alzheimer’s Association, told Fox News Digital. Researchers could enroll people at stages where an intervention has the best chance to show benefit.
“A blood test is generally much less expensive and easier to administer than a brain scan or spinal‑fluid test. In the future, it could help doctors and researchers identify people who may benefit from early treatments,” added Edelmayer, who was not involved in the study. That accessibility is central to making prevention studies feasible on a large scale and finding candidates for drugs that aim to slow or prevent decline.
The investigators do note limits. “We were only able to make predictions for individuals whose p-tau217 levels fell within a certain range, although it was a fairly wide range,” Petersen shared. “The models were developed in relatively healthy and well-educated research cohorts that were not diverse, so the results may not apply well to the broader population.” That means caution is warranted before translating the model to clinics that serve varied communities.
The team also warned against jumping to home testing or one-off screenings without clinical guidance. “At this point, we do not recommend that any cognitively unimpaired individuals have any Alzheimer’s disease biomarker test,” Dr. Suzanne Schindler, a neurologist at Washington University who was a co-author of the study, said in the press release. “The current estimate is not yet accurate enough for clinical use or personal medical decision-making, but we expect that it will be possible to create more accurate models,” he told Fox News Digital.
Looking forward, researchers plan to refine predictions by adding other blood and imaging biomarkers and cognitive measures, and by recruiting more diverse volunteers to validate results. Two large clinical trials are underway testing whether people with high p-tau217 can benefit from early treatment with drugs designed to reduce brain plaques. “There are many other blood and imaging biomarkers, as well as cognitive tests, that we can combine with plasma p-tau217 to improve the accuracy of predicting symptom onset,” Petersen said. “We hope this work will lead to even better models that will be useful to individuals.”
